- Home
- OXY vs EW Comparison
OXY vs EW Comparison
Compare OXY & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXY | EW |
|---|---|---|
| Founded | 1920 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 45.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | OXY | EW |
|---|---|---|
| Price | $39.77 | $86.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 20 |
| Target Price | $49.73 | ★ $95.83 |
| AVG Volume (30 Days) | ★ 8.5M | 3.0M |
| Earning Date | 11-10-2025 | 02-10-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.39 | ★ 2.33 |
| Revenue | ★ $26,601,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ $28.66 | $37.99 |
| Revenue Growth | N/A | ★ 10.60 |
| 52 Week Low | $34.79 | $65.94 |
| 52 Week High | $53.20 | $87.89 |
Technical Indicators
Market Signals| Indicator | OXY | EW |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 60.06 |
| Support Level | $39.72 | $85.79 |
| Resistance Level | $40.47 | $86.98 |
| Average True Range (ATR) | 0.82 | 1.55 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 29.91 | 95.71 |
Price Performance
Historical ComparisonAbout OXY Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 52% oil and natural gas liquids and 48% natural gas.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.